The third quarter of 2022 saw progress in several areas, such as the construction of the laboratory facilities in Campus Solna in Stockholm, the setup of a simulation laboratory in Linköping […]
STOCKHOLM – October 26, 2022 Inify Laboratories, a fully integrated digital ultramodern laboratory services within pathology that provides cancer diagnostics, is advancing towards opening of the company’s new laboratory, situated […]
Stockholm, Sweden, August 30, 2022; Today, the 30th of August 2022, Inify Laboratories AB, org. no. 559345-4431, held an extraordinary general meeting in Stockholm. Total 31,807,064 shares were represented at […]
Stockholm, Sweden, August 19, 2022 – Inify Laboratories AB (“Inify”) has been notified that the following transaction has been completed by a close associate to a primary insider in Inify: […]
STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on […]
STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda […]
STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda […]
Stockholm, June 29th 2022 Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as […]
“Today I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK […]
Stockholm, June 16, 2022 Oslo Børs has decided to admit Inify Laboratories AB to trading. It is stipulated that the company prior to the first day of trading must satisfy […]